![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Pyridostigmine Bromide, generic version of Mestinon, is a cholinesterase inhibitor small molecule drug administered orally as a syrup for myasthenia gravis.
Lead Product(s): Pyridostigmine
Therapeutic Area: Immunology Product Name: Mestinon-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Milla Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.
Lead Product(s): Pyridostigmine
Therapeutic Area: Immunology Product Name: Pyridostigmine Bromide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alter Pharma group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022